title: Epidermal growth factor receptor and variant III targeted immunotherapy.
abstract: Immunotherapeutic approaches to cancer have shown remarkable promise. A critical barrier to successfully executing such immune-mediated interventions is the selection of safe yet immunogenic targets. As patient deaths have occurred when tumor-associated antigens shared by normal tissue have been targeted by strong cellular immunotherapeutic platforms, route of delivery, target selection and the immune-mediated approach undertaken must work together to maximize efficacy with safety. Selected tumor-specific targets can spare potential toxicity to normal tissue; however, they are far less common than tumor-associated antigens and may not be present on all patients. In the context of immunotherapy for high-grade glioma, 2 of the most prominently studied antigens are the tumor-associated epidermal growth factor receptor and its tumor-specific genetic deletion variant III. In this review, we will summarize the immune-mediated strategies employed against these targets as well as the caveats particular to these approaches.
authors.affiliation: The Preston Robert Tisch Brain Tumor Center (K.L.C., P.C.G., C.M.S., J.H.S.); Division of Neurosurgery, Department of Surgery, Duke University Medical Center Durham, North Carolina (K.L.C., P.C.G., C.M.S., J.H.S.); Department of Biomedical Engineering, Duke University Durham, North Carolina (P.C.G.); Department of Pathology, Duke University Medical Center Durham, North Carolina (J.H.S.); Department of Immunology, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center Houston, Texas (A.B.H.).
authors.forename: Kendra L
authors.initials: KL
authors.lastname: Congdon
authors.affiliation: The Preston Robert Tisch Brain Tumor Center (K.L.C., P.C.G., C.M.S., J.H.S.); Division of Neurosurgery, Department of Surgery, Duke University Medical Center Durham, North Carolina (K.L.C., P.C.G., C.M.S., J.H.S.); Department of Biomedical Engineering, Duke University Durham, North Carolina (P.C.G.); Department of Pathology, Duke University Medical Center Durham, North Carolina (J.H.S.); Department of Immunology, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center Houston, Texas (A.B.H.).
authors.forename: Patrick C
authors.initials: PC
authors.lastname: Gedeon
authors.affiliation: The Preston Robert Tisch Brain Tumor Center (K.L.C., P.C.G., C.M.S., J.H.S.); Division of Neurosurgery, Department of Surgery, Duke University Medical Center Durham, North Carolina (K.L.C., P.C.G., C.M.S., J.H.S.); Department of Biomedical Engineering, Duke University Durham, North Carolina (P.C.G.); Department of Pathology, Duke University Medical Center Durham, North Carolina (J.H.S.); Department of Immunology, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center Houston, Texas (A.B.H.).
authors.forename: Carter M
authors.initials: CM
authors.lastname: Suryadevara
authors.affiliation: The Preston Robert Tisch Brain Tumor Center (K.L.C., P.C.G., C.M.S., J.H.S.); Division of Neurosurgery, Department of Surgery, Duke University Medical Center Durham, North Carolina (K.L.C., P.C.G., C.M.S., J.H.S.); Department of Biomedical Engineering, Duke University Durham, North Carolina (P.C.G.); Department of Pathology, Duke University Medical Center Durham, North Carolina (J.H.S.); Department of Immunology, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center Houston, Texas (A.B.H.).
authors.forename: Hillary G
authors.initials: HG
authors.lastname: Caruso
authors.affiliation: The Preston Robert Tisch Brain Tumor Center (K.L.C., P.C.G., C.M.S., J.H.S.); Division of Neurosurgery, Department of Surgery, Duke University Medical Center Durham, North Carolina (K.L.C., P.C.G., C.M.S., J.H.S.); Department of Biomedical Engineering, Duke University Durham, North Carolina (P.C.G.); Department of Pathology, Duke University Medical Center Durham, North Carolina (J.H.S.); Department of Immunology, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center Houston, Texas (A.B.H.).
authors.forename: Laurence J N
authors.initials: LJ
authors.lastname: Cooper
authors.affiliation: The Preston Robert Tisch Brain Tumor Center (K.L.C., P.C.G., C.M.S., J.H.S.); Division of Neurosurgery, Department of Surgery, Duke University Medical Center Durham, North Carolina (K.L.C., P.C.G., C.M.S., J.H.S.); Department of Biomedical Engineering, Duke University Durham, North Carolina (P.C.G.); Department of Pathology, Duke University Medical Center Durham, North Carolina (J.H.S.); Department of Immunology, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center Houston, Texas (A.B.H.).
authors.forename: Amy B
authors.initials: AB
authors.lastname: Heimberger
authors.affiliation: The Preston Robert Tisch Brain Tumor Center (K.L.C., P.C.G., C.M.S., J.H.S.); Division of Neurosurgery, Department of Surgery, Duke University Medical Center Durham, North Carolina (K.L.C., P.C.G., C.M.S., J.H.S.); Department of Biomedical Engineering, Duke University Durham, North Carolina (P.C.G.); Department of Pathology, Duke University Medical Center Durham, North Carolina (J.H.S.); Department of Immunology, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center Houston, Texas (A.B.H.).
authors.forename: John H
authors.initials: JH
authors.lastname: Sampson
mesh_terms: D000818:Animals; D001932:Brain Neoplasms; D064987:Cell- and Tissue-Based Therapy; D066246:ErbB Receptors / Q000276:immunology*; D005910:Glioma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy
chemical_list: C410723:epidermal growth factor receptor VIII; D066246:ErbB Receptors
keywords: epidermal growth factor receptor; glioma; immunology; immunotherapy